[Event Report] FY2023 AMR Alliance Japan Planning Meeting (February 2, 2023)
date : 3/9/2023
Tags: AMR
AMR Alliance Japan (Secretariat: Health and Global Policy Institute) held a meeting to discuss its FY2023 plans among Alliance members.
AMR Alliance Japan, as an independent platform for multisector discussion with the mission of contributing to the improvement of public health by promoting measures on AMR, will continue to work with Alliance members and partner organizations to deepen policy debate around AMR.
■Overview
Date and time: Thursday, February 2, 2023
Organizer: AMR Alliance Japan (Secretariat: HGPI)
■Discussion
Participants (Titles omitted; in no particular order)
Kazuyuki Akai (Director, Business Development, Nippon Becton Dickinson Company Ltd.)
Hiroshi Itoh (Internal Medicine, Medical Affairs, Pfizer Japan Inc.)
Rie Ueno (BioMérieux Japan Ltd, Director Medical Affairs)
Kazunobu Ouchi (President, Japanese Society for Pediatric Infectious Diseases / Specially Appointed Professor, Department of Medical Welfare for Children, Faculty of Health and Welfare, Kawasaki University of Medical Welfare / Specially Appointed Manager, Kawasaki Medical School General Medical Center / Professor emeritus, Kawasaki Medical School)
Akio Ozaki (Director, Public and Industry Policy, Health Policy, MSD K. K.)
Katsunori Kanazawa (Officer Infectious Diseases, Medical Information, Sumitomo Pharma Co., Ltd.)
Satoshi Kamayachi (Executive Board Member, Japan Medical Association)
Takashi Kitahara (Chairman, Japan Pharmaceutical Association / Professor, Department of Clinical Pharmacology, Yamaguchi University)
Takuko Sawada (Director of the Board, Executive Vice President, Shionogi & Co., Ltd.)
Hayato Shishido (Manager, Business Development Department, Research & Development Division, NISSUI PHARMACEUTICAL CO., LTD)
Kazutoshi Shibuya (President, The Japanese Society for Medical Mycology / Professor, Department of Surgical Pathology, Toho University)
Mitsuru Sugawara (President, Japanese Society of Therapeutic Drug Monitoring / Department of Pharmacy, Hokkaido University Hospital / Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University)
Yoshisaburo Takahashi (General Manager, Vaccine/Infections Dept., Meiji Seika Pharma Co., Ltd.)
Hiroshi Taki (Manager, Policy & Public Affairs, Pfizer Japan Inc.)
Kazuhiro Tateda (Chairman, the Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery / Professor, Department of Microbiology and Infectious Diseases, Toho University)
Yasunori Tawaragi (Director, AMR Incentives and Advocacy TF, Japan Pharmaceutical Manufacturers Association)
Mitsuaki Nagasawa (Vice-president, Japanese Association of Medical Technologists)
Testuya Matsumoto (President, Japanese Society of Chemotherapy / President, Japanese society for clinical microbiology / Chief Professor, Department of Infectious Diseases, International University of Health and Welfare Graduate School of Medicine)
Megumi Maruyama (Global Health Officer, Sumitomo Pharma Co., Ltd.)
Yuichi Muraki (Representative, Japanese Society of Pharmaceutical Health Care and Sciences / Professor, Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University)
Akira Yuasa (Senior Manager, HTA/HEOR, Corporate Affairs, Health & Value, Pfizer Japan Inc.)
Masaki Yoshida (President, Japanese Society for Infection Prevention and Control)
Hiroshi Yotsuyanagi (President, Japanese Association for Infectious Diseases / Director, IMUST Hospital, Institute of Medical Science, University of Tokyo)
Moderator:
Yui Kohno (Manager, Health and Global Policy Institute)
日本語
Top Research & Recommendations Posts
- [Report and Recommendations] Discussion Points in Healthcare DX Project Expert Panel Meeting (April 2, 2024)
- [Event Report] Planetary Health Expert Meeting Aiming for Sustainable Healthcare: Learning from the Impact of Environmental Pollution and Medical Waste During the Pandemic (February 16, 2024)
- [Announcement] A Significant Step Towards the Building a Green Healthcare System: Support for the Formal Expression of Interest by the Japanese Government Delegation to the ATACH at the Executive Board Meeting of the WHO (February 16, 2024)
- [Policy Recommendations] Obesity Control Promotion Project 2023 “The Next Steps for Engaging and Cooperating with Patients, Citizens, and Communities for Implements of Obesity Control Measurements” (April 8, 2024)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Policy Recommendations] Kidney Disease Control Promotion Project 2023 “Establishing Kidney Disease Control Measures with Patient, Citizen, and Community Engagement and Collaboration” Policy Recommendations, a Collection of Good Practices of Chronic Kidney Disease (CKD) and Control Measures in Local Governments (February 14, 2024)
- [Announcement] HGPI Joins Global Climate and Health Alliance (March 23, 2024)
- [Research Report] Survey of Japanese Physicians Regarding Climate Change and Health (December 3, 2023)
- [Research Report] “International comparison of dementia policies, research study on information dissemination.” (April 10, 2024)
- [Research Report] 2019 Survey on Healthcare in Japan
Featured Posts
-
2024-04-22
[Registration Open] (Hybrid Format) Intractable Disease Day Symposium: Future Measures for Intractable Diseases from the Perspectives of Patients and Citizens (May, 23 2024)
-
2024-04-23
[Registration Open] The 125th HGPI Seminar: Progress and Prospects for Domestic Measures on Health Problems Caused by Alcohol (May 24 , 2024)
-
2024-04-26
[Policy Recommendations] Obesity Control Promotion Project 2023 “The Next Steps for Engaging and Cooperating with Patients, Citizens, and Communities for Implements of Obesity Control Measurements” (April 8, 2024)
-
2024-05-01
[Registration Open] The Global Health Education Program (G-HEP) 2024 (May 1, 2024)
-
2024-05-02
[Announcement] Recruitment of the Health Policy Academy the 13th Session